Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Feb 2019 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 31 Aug 2018 Biomarkers information updated
- 14 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.